(Q37969770)

English

Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer

scientific article published on December 19, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kirsten Vang Nielsen

5

object named as

Kirsten Vang Nielsen

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22181013

20 December 2024

author name string

Niels Frank Jensen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

David Hersi Smith

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sune Boris Nygård

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Maria Unni Rømer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Nils Brünner

6

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

full work available at URL

http://www.tandfonline.com/doi/pdf/10.3109/00365521.2012.640835

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

340-355

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Banking of biological fluids for studies of disease-associated protein biomarkers

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

5-Fluorouracil: mechanisms of action and clinical strategies

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidylate synthase expression in stage II and III colon cancer: a retrospective review

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

The dual role of thymidine phosphorylase in cancer development and chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Genetic prognostic and predictive markers in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Protein Kinase CK2 Is a Central Regulator of Topoisomerase I Hyperphosphorylation and Camptothecin Sensitivity in Cancer Cell Lines

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Molecular determinants of irinotecan efficacy.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Cellular and molecular aspects of drugs of the future: oxaliplatin.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Molecular mechanisms of resistance and toxicity associated with platinating agents

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Cisplatin: mode of cytotoxic action and molecular basis of resistance

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

ERCC1-XPF endonuclease facilitates DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

The eukaryotic nucleotide excision repair pathway

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Mechanism of open complex and dual incision formation by human nucleotide excision repair factors

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

Mammalian DNA ligases

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640835

21 January 2018

In vitro drug responses in primary and metastatic colorectal cancers

2

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

4

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil

13

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

26

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants

48

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

57

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

66

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

The Mechanism of Action of Antitumor Platinum Compounds

67

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Oxaliplatin-induced damage of cellular DNA

68

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study

73

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

82

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

83

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

DNA polymerase delta mediates excision repair in growing cells damaged with ultraviolet radiation.

88

1 reference

10.3109/00365521.2012.640835

https://api.crossref.org/works/10.3109/00365521.2012.640835

20 December 2024

Identifiers

10.3109/00365521.2012.640835

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37969770&oldid=2289948944"